Shares of Celldex Therapeutics (CLDX) have gained 5.2% over the past four weeks to close the last trading session at $41.21, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $69.14 indicates a potential upside of 67.8%. The mean estimate comprises seven short-term price targets with a standard deviation of $20.15. While the lowest estimate of $27 indicates a 34.5% decline from th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware No. 13-3191702 (State or other jurisdiction of incorporat ...

EXHIBIT 99.1 Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study - - Atopic dermatitis selected as next indication; Phase 2 study to ...

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study - - Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 - HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc ...

Celldex Therapeutics新闻 - Celldex Therapeutics宣布完成了barzolvolimab用于治疗慢性诱发性荨麻疹（CIndU）两种最常见形式的临床研究的患者招募[1] - Barzolvolimab是一种人源化单克隆抗体，具有高特异性结合受体酪氨酸激酶KIT的能力，并有效抑制其活性[2] - Celldex Therapeutics总裁兼首席执行官Anthony Marucci表示，barzolvolimab有望成为CIndU患者急需的潜在治疗方法，并期待在年底前公布该研究的最终数据[3]

股票走势分析 - Celldex Therapeutics (CLDX) 最近出现了明显的下降趋势，股票在过去四周下跌了14.6% [1] 技术指标解读 - RSI是一种常用的技术指标，用于判断股票是否被卖空 [2] - RSI在0到100之间波动，当股票的RSI低于30时通常被认为是被卖空的 [3] - RSI有助于快速检查股票价格是否即将反转 [4]

Celldex Therapeutics (CLDX)盈利预期 - Celldex Therapeutics (CLDX) 最近被升级为 Zacks Rank 2 (Buy) [1] - Celldex的盈利前景积极，可能会带来购买压力和股价上涨 [4] - Celldex的盈利预期在过去三个月内增长了13.8% [10] - Celldex的升级为Zacks Rank 2，使其位于Zacks覆盖股票中前20%，暗示股价可能在短期内上涨 [13] Zacks评级系统 - Zacks评级系统主要跟踪卖方分析师对股票的盈利预期，这对于个人投资者非常有用 [2] - 盈利预期的变化对股价走势有着强烈的相关性 [5] - Zacks评级系统将股票分为五组，其中排名前20%的股票被认为具有较高的盈利预期修订特性 [11]

股价走低 - Celldex Therapeutics (CLDX) 最近股价一直走低，遭受了显著的抛售压力[1] RSI技术指标 - RSI是一种常用的技术指标，用于判断股票是否被超卖[2] - RSI在0到100之间波动，当股票的RSI指数低于30时通常被认为是超卖状态[3] - RSI有助于快速检查股票价格是否即将反转[4]

Celldex Therapeutics (CLDX) closed the last trading session at $40.49, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $69.57 indicates a 71.8% upside potential. The mean estimate comprises seven short-term price targets with a standard deviation of $20.30. While the lowest estimate of $27 indicates a 33.3% decline from the current price level, the most optimistic anal ...

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an "Inflammation & Immunology Corporate Panel Discussion" at TD Cowen's 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the Celldex website. A replay of the webcast will be ava ...